Evidence map›Paper›PMID 29562882›Full record

ArticleBMC immunology2018

Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications.

John Sidney, Jose Luis Vela, Dave Friedrich, Ravi Kolla, Matthias von Herrath, Johnna D Wesley, Alessandro Sette

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Neuron-reactive KIRNature communications · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Posttranslational modifications in diabetes: Mechanisms and functions.Reviews in endocrine & metabolic disorders · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

John SidneyLa Jolla Institute for Allergy and Immunology, La Jolla, CA, 92130, USA. jsidney@lji.org.ORCID 0000-0002-0987-405X
Jose Luis VelaNovo Nordisk Research Center Seattle, Inc., 530 Fairview Ave N, Seattle, WA, 98109, USA.
Dave FriedrichNovo Nordisk Research Center Seattle, Inc., 530 Fairview Ave N, Seattle, WA, 98109, USA.
Ravi KollaLa Jolla Institute for Allergy and Immunology, La Jolla, CA, 92130, USA.
Matthias von HerrathNovo Nordisk Research Center Seattle, Inc., 530 Fairview Ave N, Seattle, WA, 98109, USA.
Johnna D WesleyNovo Nordisk Research Center Seattle, Inc., 530 Fairview Ave N, Seattle, WA, 98109, USA.
Alessandro SetteLa Jolla Institute for Allergy and Immunology, La Jolla, CA, 92130, USA.
Novo Nordisk (United States) · USLa Jolla Institute for Immunology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 1 diabetes (T1D) is thought to be an autoimmune disease driven by anti-islet antigen responses and mediated by T-cells. Recent published data suggests that T-cell reactivity to modified peptides, effectively neoantigens, may promote T1D. These findings have given more credence to the concept that T1D may not be solely an error of immune recognition but may be propagated by errors in protein processing or in modifications to endogenous peptides occurring as result of hyperglycemia, endoplasmic reticulum (ER) stress, or general beta cell dysfunction. In the current study, we hypothesized that diabetes-associated epitopes bound human leukocyte antigen (HLA) class I poorly and that post-translational modifications (PTM) to key sequences within the insulin-B chain enhanced peptide binding to HLA class I, conferring the CD8+ T-cell reactivity associated with T1D.

resultsWe first identified, through the Immune Epitope Database (IEDB; www.iedb.org ), 138 published HLA class I-restricted diabetes-associated epitopes reported to elicit positive T-cell responses in humans. The peptide binding affinity for their respective restricting allele(s) was evaluated in vitro. Overall, 75% of the epitopes bound with a half maximal inhibitory concentration (IC50) of 8250 nM or better, establishing a reference affinity threshold for HLA class I-restricted diabetes epitopes. These studies demonstrated that epitopes from diabetes-associated antigens bound HLA with a lower affinity than those of microbial origin (binding threshold of 500 nM for 85% of the epitopes). Further predictions suggested that diabetes epitopes also bind HLA class I with lower affinity than epitopes associated with other autoimmune diseases. Therefore, we measured the effect of common PTM (citrullination, chlorination, deamidation, and oxidation) on HLA-A*02:01 binding of insulin-B-derived peptides, compared to native peptides. We found that these modifications increased binding for 44% of the insulin-B epitopes, but only 15% of the control peptides.

conclusionsThese results demonstrate that insulin-derived epitopes, commonly associated with T1D, generally bind HLA class I poorly, but can be subject to PTM that improve their binding capacity and may, in part, be responsible for T-cell activation in T1D and subsequent beta cell death.

Indexed as

Protein Processing, Post-TranslationalAmino Acid SequenceCD8-Positive T-LymphocytesDiabetes Mellitus, Type 1Epitopes, T-LymphocyteHistocompatibility Antigens Class IHLA AntigensHumansInsulinPeptidesProtein BindingEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA AntigensInsulinPeptidesClass I MHCDiabetesHLA-peptide binding affinityInsulinT cell epitopes

Identifiers

PMID29562882
PMCPMC5863483
OpenAlexW2804615179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.